Project description:The goals of this study were to evaluate changes in microRNA expression following androgen treatment. Four treatment groups were studied: untreated and those treated with 0.1, 1.0, and 10.0 nM of synthetic androgen (R1881). Data is relative to the untreated sample.
Project description:The goals of this study were to evaluate changes in microRNA expression following androgen treatment. Four treatment groups were studied: untreated and those treated with 0.1, 1.0, and 10.0 nM of synthetic androgen (R1881). Data is relative to the untreated sample.
Project description:Aberrant androgen receptor (AR)-mediated transcription is a critical driver in progression of human prostate cancer. It's known that different doses of androgens can elicit differential transcriptional and proliferative responses in prostate-tumor cells. Here, we set out to examine the androgenic regulation of glycoprotein expression in the membrane fraction of prostate-tumor cells that could serve as mediators or markers of androgen-induced proliferative responses observed in prostate-tumor cells. A bioanalytical workflow involving lectin-affinity chromatography and label-free quantitative mass spectrometry was used to identify androgen-sensitive glycomembrane protein expression associated with androgen-mediated proliferation. This study would facilitate the identification of surface membrane proteins involved in androgen-mediated proliferation and provide potential therapeutic targets in the detection treatment of proliferation prostate-tumors.
Project description:Rapid immunoprecipitation mass spectrometry of endogenous protein (RIME) was conducted to examine interactome of androgen receptor (AR) in LNCaP cells.
Project description:This SuperSeries is composed of the following subset Series: GSE16212: Androgen repsonsive microRNAs in LNCaP cell Lines GSE16213: Androgen repsonsive microRNAs in LAPC-4 cell lines Refer to individual Series
Project description:RNA-Seq analysis of prostate cancer cell line LNCaP treated with vehicle (C), androgen (R), androgen and IMTPPE (R + IMTPPE), androgen and JJ-(+)-450 (androgen + (-)450), androgen and JJ-(-)450 (androgen + (-)450), androgen and enzalutamide (androgen +Enz). To evaluate if our compounds can inhibit AR function specifically and completely, LNCaP mRNA profiles of cells treated with IMTPPE, (+)-JJ-450 and (-)-JJ-450, comparing to enzalutamide. RNA isolation was performed using RNeasy Mini kit (Qiagen), RNA Sequencing was carried out by Genomics Research Core of University of Pittsburgh using Illumina NextSeq 500 system. The sequence reads that passed FASTQC were analyzed at the transcript level. Each sample was mapped to the Human Ensembl reference genome GRCh38. We definied different expression genes with a fold change ≥2.0 and FDR <0.05. Both (-)-JJ-450 and enzalutamide are very specific to AR, with 56 and 186 DE genes comparing to control samples respectively. IMTPPE and (+)-JJ-450 can inhibit most of the androgen responsive genes, but also some other genes were affected. (-)-JJ-450 is a novel compound inhibts AR function specifically and completely, and it is a potential lead compound for the treatment of CRPC, including those resistant to enzalutamide.
Project description:In this work we reported in a high-throughput way (RIP-seq) the RNAs associated with androgen receptor after treatment with androgen hormone. We used a large compilation of lincRNAs to describe the differences between lincRNAs associated to androgen receptor from those who are non-associated with androgen receptor. By integrating different data sources (DNA-seq Seq and CHIP-seq) was possible to describe transcription factors and histone marks diffrentially enriched at the promoter and vicinity of androgen associated lincRNA loci.
Project description:Gedunin is a natural product that affects LNCaP androgen-signalling by 24h We used microarrays to detail the androgen-responsive program of gene expression affected by gedunin treatment at 24h Keywords: drug treatment
Project description:celastrol is a natural product that affects LNCaP androgen-signalling by 24h We used microarrays to detail the androgen-responsive program of gene expression affected by celastrol treatment at 24h Keywords: drug treatment